MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Bristol-Myers Squibb Company Total Current Liabilities 2011-2026 | BMY
Annual Total Current Liabilities Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.4 B | 23.8 B | 22.3 B | 21.9 B | 21.9 B | 19.1 B | 18.3 B | 10.7 B | 9.56 B | 8.84 B | 8.02 B | 8.46 B | 12.4 B | 8.28 B | 7.78 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.8 B | 7.78 B | 15 B |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Assembly Biosciences
ASMB
|
48.8 M | $ 28.46 | 3.45 % | $ 319 M |  USA |
 |
Axsome Therapeutics
AXSM
|
379 M | $ 156.92 | -1.23 % | $ 7.81 B | USA |
 |
Galera Therapeutics
GRTX
|
645 K | - | -32.59 % | $ 7.61 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
60.7 M | $ 1.37 | -4.2 % | $ 350 M |  Britain |
 |
I-Mab
IMAB
|
576 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | USA |
 |
Benitec Biopharma
BNTC
|
1.8 M | $ 10.98 | -4.52 % | $ 452 M | USA |
 |
Compugen Ltd.
CGEN
|
22.6 M | $ 2.09 | -0.95 % | $ 195 M |  Israel |
 |
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | USA |
 |
PainReform Ltd.
PRFX
|
2.44 M | $ 2.28 | -0.44 % | $ 1.03 M | Israel |
 |
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M |  Canada |
|
Foghorn Therapeutics
FHTX
|
59.7 M | $ 5.0 | 2.25 % | $ 315 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | USA |
 |
AbCellera Biologics
ABCL
|
64.3 M | $ 3.4 | -3.68 % | $ 1.02 B | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
759 M | $ 54.13 | -1.64 % | $ 10.4 B | USA |
 |
Curis
CRIS
|
19 M | $ 0.77 | 1.89 % | $ 4.86 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | USA |
 |
AgeX Therapeutics
AGE
|
5.91 M | - | -10.17 % | $ 12.2 K | USA |
 |
Coherus BioSciences
CHRS
|
140 M | $ 1.52 | -5.59 % | $ 178 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | USA |
 |
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
22.5 M | $ 4.24 | -2.97 % | $ 704 M | Canada |
 |
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | USA |
 |
AIkido Pharma
AIKI
|
3.78 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cardiff Oncology
CRDF
|
16.4 M | $ 1.8 | -1.1 % | $ 120 M | USA |
 |
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | USA |
 |
Cabaletta Bio
CABA
|
16 M | $ 2.94 | -3.29 % | $ 3.43 M | USA |
 |
Iterum Therapeutics
ITRM
|
17.6 M | $ 0.16 | -5.45 % | $ 3.15 M |  Irlanda |
 |
Brickell Biotech
BBI
|
1.66 M | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M | USA |